Oncology nurses are in the forefront of helping their patients manage CINV. This section, created especially for nurses, will help you identify the patients suitable for SANCUSO, download tools for use in your practice, and watch informative videos.

  • SANCUSO® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/ or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration1
  • Due to its route of administration, SANCUSO may be an option for chemotherapy patients who are unable to take or retain oral antiemetics1,11

 

Do you recognize these patients?

Patients with previous breakthrough symptoms

  • Patients may experience a decrease in therapeutic effect when drug plasma levels are low36
  • Repeated administration of oral medication, such as antiemetics, over several days can give rise to peaks and troughs in plasma drug levels34

Experienced CINV on their previous cycle of chemotherapy. SANCUSO is not a
   rescue medication for breakthrough symptoms.

Experienced CINV on their previous cycle of chemotherapy.
  SANCUSO is not a rescue medication for breakthrough
  symptoms.


Patients receiving multiday chemotherapy

  • Multiday regimens, which are often highly emetogenic, may result in consecutive periods of acute CINV37

Patients who are forgetful

  • Patients may experience forgetfulness or cognitive impairment due to their chemotherapy regimen38,39
  • Forgetting to take a daily oral antiemetic may result in breakthrough nausea and vomiting40**

**SANCUSO is not indicated for breakthrough symptoms


Patients taking polypharmacy

  • Poor treatment adherence may result due to complex treatment regimens38
  • The rate of adherence to medications decreases as the dosing frequency increases38

 

Protect your mechanically compromised cancer patients from CINV*

  • Because SANCUSO is a patch that provides up to 5 days of prevention against CINV,1,34 your patients need not swallow antiemetic pills every day
  • Because SANCUSO is absorbed through the skin, it bypasses the gastrointestinal tract and is not hindered by motility issues or blockages1,11 that may limit absorption of oral medications

Patients who have difficulty swallowing

  • Patients may experience difficulty swallowing as a result of certain cancer types (eg, head and neck), or treatment regimens2

Patients receiving combination radiation/chemotherapy

  • Combination radiation/chemotherapy contributes to oral mucositis and difficulty swallowing3

Patients with limited gut motility/absorption

  • Malignancy-associated delayed gastric emptying may lead to changes in the absorption of orally administered drugs such as antiemetics4,5

Patients with oral mucositis

  • The risk of oral mucositis increases with certain chemotherapeutic agents or combination radiation/chemotherapy6
  • SANCUSO provides another option for these patient types

* Mechanically compromised cancer patients include those with oral and/or gastrointestinal impairment associated with chemotherapy, with or without radiation,2,3,7,8 or tumor burden,9,10 who may be unable to take or retain oral antiemetics.11
SANCUSO is not indicated for radiation induced nausea and vomiting.

When to consider SANCUSO

Are your chemotherapy patients experiencing disease- or treatment-related complications that may make it difficult to take or retain oral antiemetics?

Learn which cancer types and treatment regimens are more likely to make patients unable to take or retain oral antiemetics


Download PDF

Helpful resources next